Trial no.:
|
PACTR202404706815223 |
Date of Approval:
|
26/04/2024 |
Trial Status:
|
Registered in accordance with WHO and ICMJE standards |
|
TRIAL DESCRIPTION |
Public title
|
Role of Liquid Chlorophyll As Adjuvant Therapy In Children With Beta Thalassemia |
Official scientific title |
Role of Liquid Chlorophyll As Adjuvant Therapy In Children With Beta Thalassemia |
Brief summary describing the background
and objectives of the trial
|
Thalassemia is a group of genetic disorders resulting from defects in the rate of synthesis of globin chains in haemoglobin molecule.
Blood transfusion therapy is a lifesaving treatment for these patients. However, the complication of this therapy is iron overload caused by recurrent blood transfusion which transmits 200 to 250 mg of iron to the patient's body per unit. The mechanism involved in iron overload damage has been thought to be associated with oxidative stress or excessive reactive oxygen species (ROS) generation.
Chlorophyll has a porphyrin ring similar to that of heme in haemoglobin.Chlorophyll has antioxidant activity; it has the ability to scavange long lived free radicals.The aim of this study is to evaluate role of liquid chlorophyll as adjuvant therapy in children with beta thalassemia. |
Type of trial |
RCT |
Acronym (If the trial has an acronym then please provide) |
|
Disease(s) or condition(s) being studied |
Haematological Disorders,Paediatrics |
Sub-Disease(s) or condition(s) being studied |
|
Purpose of the trial |
Treatment: Drugs |
Anticipated trial start date |
15/05/2024 |
Actual trial start date |
|
Anticipated date of last follow up |
15/10/2024 |
Actual Last follow-up date |
|
Anticipated target sample size (number of participants) |
70 |
Actual target sample size (number of participants) |
|
Recruitment status |
Not yet recruiting |
Publication URL |
|
|